All In MedTech

Device Trial Radar · NCT04292405

Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

60

Actual

Start

Jan 23, 2020

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Zoll Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Mar 3, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.

Conditions

  • Heart Failure

Interventions

  • Wearable Cardioverter DefibrillatorDevice

    Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CABs comparisonTime frame: 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MAYO Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.